After joining with Endo earlier this year, Mallinckrodt has completed its restructuring with the spinout of generic and sterile injectables unit Par Health, emerging from the process with a new. Mallinckrodt looks like it could join Purdue Pharma in reaching a settlement in its bankruptcy proceedings related to opioid litigation, after years of legal wrangling. The Ireland-headquartered. Mallinckrodt Inc. manufactures, markets and/or distributes more than 31 drugs in the U.S. Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it had 5,500 employees and sales of $3.2 billion, of which $2.9 billion was from the U.S. healthcare system. [3] On August 1, 2025, it was announced that the firm had merged its operations with those of Endo. [4] Mallinckrodt Pharmaceuticals combined with Endo in 2025 to better serve customers and improve outcomes for the patients we support. From this union, we established two focused, standalone. Some three months after merging, Mallinckrodt and Endo have successfully spun off their combined sterile injectables and generics businesses. Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products. The area of focus is neonatal critical care respiratory therapies. About Mallinckrodt Ikaria Aust Pty Ltd a part of Mallinckrodt Pharmaceuticals. We are a specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future. Learn More Our Products Producing high-quality, specialty treatments INOmax® Learn More Product Monograph Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.